Background Immunologic and inflammatory adverse effects following vaccination against COVID-19 are being reported. While some reactions may develop denovo others concern its immunogenic effect in patients with pre-existing inflammatory conditions. Methods Retrospective consecutive patients diagnosed with ocular inflammatory manifestations within 8 weeks of receiving COVID-19 vaccination who presented to a tertiary eye care centre in South India. Results Ninety-eight eyes of 67 patients presenting with ocular inflammatory manifestations within 8 weeks following COVID-19 vaccination were studied. The mean age was 43 years (+/- 14.82; range 19–80 years). The most common presentations were anterior uveitis ( n = 31, 31.7%), followed by panuveitis ( n = 24, 24.5%). The mean time to onset of symptoms was 25 days (+/- 15.48; range 2–55 days) following a dose of vaccine. Among all patients, 39 (58.2%) had a previous history of ocular inflammation. Mean presenting visual acuity was 0.4 (0-4) logMAR units and mean final visual acuity was 0.2 (0-4) logMAR units. The causes for reduced vision included of cystoid macular edema ( n =2, 2%), chorioretinal atrophy ( n =2.2%), optic atrophy ( n =1.1%), retinal vascular occlusion ( n =1.1%) and acute retinal necrosis ( n =1.1%). Conclusion Infective and immunogenic adverse events should be watched out for after COVID-19 vaccination. It is difficult to establish causality for such manifestations, nevertheless, most of them were mild and had good final visual outcomes. Supplementary Information The online version contains supplementary material available at 10.1186/s12348-023-00358-x.
【저자키워드】 COVID-19, coronavirus disease, SARS-CoV-2, vaccination, Uveitis, Immunologic, Ocular inflammation, vaccine-associated uveitis, scleritis,